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Abstract
Background: We previously demonstrated in vitro that zidovudine (AZT) selects for A371V in the connection domain and
Q509L in ribonuclease H (RNase H) domain of HIV-1 reverse transcriptase (RT) which, together with the thymidine analog
mutations D67N, K70R and T215F, confer greater than 100-fold AZT resistance. The goal of the current study was to
determine whether AZT monotherapy in HIV-1 infected patients also selects the A371V, Q509L or other mutations in the C-
terminal domains of HIV-1 RT.
Methodology/Principal Findings: Full-length RT sequences in plasma obtained pre- and post-therapy were compared in 23
participants who received AZT monotherapy from the AIDS Clinical Trials Group study 175. Five of the 23 participants
reached a primary study endpoint. Mutations significantly associated with AZT monotherapy included K70R (p = 0.003) and
T215Y (p = 0.013) in the polymerase domain of HIV-1 RT, and A360V (p = 0.041) in the connection domain of HIV-1 RT. HIV-1
drug susceptibility assays demonstrated that A360V, either alone or in combination with thymidine analog mutations,
decreased AZT susceptibility in recombinant viruses containing participant-derived full-length RT sequences or site-directed
mutant RT. Biochemical studies revealed that A360V enhances the AZT-monophosphate excision activity of purified RT by
significantly decreasing the frequency of secondary RNase H cleavage events that reduce the RNA/DNA duplex length and
promote template/primer dissociation.
Conclusions: The A360V mutation in the connection domain of RT was selected in HIV-infected individuals that received
AZT monotherapy and contributed to AZT resistance.
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Introduction
Zidovudine (39-azido-39-deoxythymidine, AZT) was the first
antiviral drug approved by the U.S. Food and Drug Administration
for the treatment of HIV infection. AZT is a nucleoside reverse
transcriptase (RT) inhibitor (NRTI) that, after metabolism by cellular
kinases to its triphosphate form (TP) in cells, competes with the
natural substrate TTP for binding and incorporation by HIV-1 RT
into the nascent viral DNA. Because AZT lacks a 39-OH on the ribose
sugar, its incorporation into viral DNA results in chain-termination.
HIV-1 resistance to AZT was first reported in 1989 [1].
Resistance was conferred by mutations in the polymerase domain
of RT that included D67N, K70R, T215Y/F and K219Q.
Subsequently, two additional AZT resistance mutations were
identified: M41L and L210W [2,3,4]. After the discovery that d4T
(29,39-didehydro-29,39-dideoxythymidine) could select the same
mutations, the term thymidine analog mutations (TAM) was
adopted to reflect their role in resistance to both AZT and d4T. In
general, each TAM alone confers between 1.5- to 4-fold resistance,
and multiple mutations are required for high-level resistance [5].
The most common combination of mutations selected includes
M41L, L210W and T215Y and excludes K70R (TAM-1
pathway). A second pattern includes D67N, K70R, T215F and
K219Q/E (TAM-2 pathway) [5]. Biochemical studies have
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demonstrated that RT containing TAMs shows an increased
capacity to unblock AZT-monophosphate (MP) terminated
primers in the presence of physiological concentrations of ATP
[6,7]. In this regard, structural studies have shown that TAMs
enhance the binding and/or placement of ATP in the HIV-1 RT
active site [8].
Recent studies have demonstrated that AZT resistance can be
increased by mutations in the connection domain of HIV-1 RT.
For example, the G333D/E, G335C, N348I, A360V/I, T369V
and A371V mutations have all be shown to augment AZT
resistance alone or in combination with TAMs [9,10,11,12].
However, all of these mutations were identified in RT sequences
from participants exposed to multiple RT inhibitors and it is not
known if these connection domain mutations were selected
specifically by AZT. For example, Yap et al reported that the
N348I mutation is highly associated with TAMs, the lamivudine
mutation M184V/I, and the non-nucleoside inhibitor resistance
mutations K103N and Y181C/I [13]. Consistent with this
observation, mechanistic analyses suggest that this mutation may
compensate for the antagonism of TAMs by M184V/I and
Y181C [14,15].
We previously carried out in vitro selection experiments by serial
passage of HIV-1 in increasing concentrations of AZT to
determine whether AZT selects mutations in the connection
and/or ribonuclease H (RNase H) domains of RT [16]. Two novel
mutations – A371V in the connection domain and Q509L in the
RNase H domain – were selected in combination with D67N,
K70R and T215F that together conferred greater than 100-fold
AZT resistance. The goal of the current study was to determine
whether AZT monotherapy in HIV-1 infected participants selects
the A371V, Q509L or other mutations in the connection or
RNase H domains of RT.
Results
Changes in serum HIV-1 RNA with AZT monotherapy
Pre-therapy and last-on-therapy serum samples were available
from 5 participants who reached a primary study endpoint (see
Methods) on AZT monotherapy and from 18 participants who did
not reach a primary study endpoint on AZT monotherapy. The
mean pre-therapy HIV-1 RNA concentration of participants
reaching a study endpoint was 33,261 copies/mL (range 3,650–
67,134 copies/mL), which was not significantly different from that
of participants not reaching a study endpoint (mean 41,002
copies/mL; range 1,439–168,576 copies/mL; p= 0.875). There
was a strong trend (p= 0.06) toward higher serum HIV-1 RNA
concentration in last-on-therapy samples from participants
reaching a primary study endpoint (mean 87,264 copies/mL;
range 35,227–216,219 copies/mL) compared with those who did
not (mean 37,424 copies/mL; range 826–138,776 copies/mL).
Mutations selected by AZT monotherapy
Table 1 shows the mutations in HIV-1 RT that emerged in
participants who received AZT monotherapy. TAMs in the
polymerase domain of RT emerged in 5 of 5 participants reaching
a study endpoint compared with 11 of 18 (61%) of participants
who did not reach a study endpoint. Although each of the known
TAMs was identified in one or more on-treatment samples, only
the K70R and T215Y mutations were significantly associated with
AZT monotherapy. Of note, the A360V in the connection domain
of HIV-1 RT was also significantly associated with AZT
monotherapy and was more frequent than the M41L, D67N,
L210W or K219E/Q mutations. A360V emerged in 2 of 5
participants who reached a study endpoint and in 4 of 18
participants who did not. Among the 6 on-treatment samples that
contained A360V, it was a pure mutant (100%) in 2 samples and a
mixture (,50%) in 4 samples, as assessed by population
sequencing (Table 2). Analysis of longitudinal samples in the 4
participants who did not reach study endpoint revealed that
A360V generally emerged at the same time as TAMs, although in
one participant it was the first mutation to emerge (Table 3). In
one of the participants who reached a study endpoint, A360V
emerged at the same time as TAMs, however in the other
participant it clearly emerged after TAMs (Table 3). The
connection domain mutation A371V was more frequent in last-
on-therapy samples compared to pre-therapy samples, but this
difference was not statistically significant (p = 0.25). The N348I
and Q509L mutations were not detected in any of the 23 on-
treatment samples.
Phenotypic analyses of HIV-1 containing A360V
To determine whether the A360V mutation conferred AZT
resistance, we first cloned full-length RTs from participant samples
4, 11 and 29 into pxxLAI-3D, and selected a single clone for
phenotypic analyses. Recombinant virus derived from participant
sample 29 did not replicate in cell culture, and was excluded from
subsequent analyses. The genotypes of the individual clones and
population sequences obtained from the participant serum are
shown in Table 2. The 360 V mutation in each of the two
replication competent viruses was reverted to A360 by mutagen-
esis and the paired (A360/360 V) recombinants were tested for
Table 1. Mutations selected by AZT monotherapy.
Domain Mutation % Pre Therapy (N) % AZT Monotherapy (N) p-valuea
Polymeraseb M41L 0.0% (0) 13% (3) 0.250
D67N 0.0% (0) 22% (5) 0.063
K70R 4.3% (1) 52% (12) ,0.001
L210W 0.0% (0) 4.3% (1) 1.0
T215Y 0.0% (0) 30% (7) 0.016
K219E/Q 0.0% (0) 13% (3) 0.250
Connection A360V 0.0% (0) 26% (6) 0.031
A371V 4.3% (1) 17% (4) 0.250
aTwo-sided McNemar’s exact test between pre-therapy and AZT-experienced (N = 23 pairs). Not corrected for multiple comparisons.
bTAMs listed in the IAS-USA 2010 drug resistance tables.
doi:10.1371/journal.pone.0031558.t001
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susceptibility to AZT (Table 4). Both recombinant viruses with RT
sequences derived from on-treatment samples were resistant to
AZT. Importantly, when the A360V mutation was reverted to
wildtype, statistically significant decreases in AZT resistance were
observed for each of the virus pairs (Table 4). We also generated a
full-length RT and polymerase domain only bulk plasmid
population for sample 3, since individual clones did not grow in
cell-culture (Table 2, see Methods). Phenotypic analyses of these
viruses further demonstrated that mutations in the connection (and/
or RNase H) domain of this particular participant isolate
contributed to AZT resistance. To further confirm the role of
A360V in AZT resistance, we generated 5 site-directed mutant
viruses in pxxLAI that contained A360V in 2 different backgrounds
of TAMs (TAM-1 and D67N/K70R). AZT susceptibility assays
(Table 5) revealed that the 360 V mutation alone confers 1.8-fold
AZT resistance compared to wildtype (p,0.05). When A360V was
in the context of TAM-1 or D67N/K70R, AZT resistance
increased 1.9- and 2.1- fold, respectively (p,0.05).
Mechanism by which A360V confers AZT resistance
TAMs in HIV-1 RT confer AZT resistance by enabling the
enzyme to excise the chain-terminating AZT-MP moiety from the
39-end of the DNA primer using ATP as a phosphate donor [7].
Previous biochemical studies demonstrated that the N348I and
Q509L mutations in HIV-1 RT indirectly increase AZT resistance
by decreasing the frequency of secondary RNase H cleavages that
reduce the RNA/DNA duplex length of the T/P and diminish the
efficiency of AZT-MP excision [13,14,23,24,26]. A similar
phenotype has been proposed for the A360V mutation; however,
the biochemical analyses reported used RTs that also contained
N348I [26]. Therefore, we performed biochemical experiments to
probe the mechanism(s) by which A360V decreased AZT
susceptibility. In this regard, we first assessed the AZT-MP
excision activity of the wildtype, TAM-1 and TAM4-1/A360V
enzymes on a well-defined DNA/DNA and RNA/DNA T/P
substrate that is routinely used in our laboratory [13,14,24,26]. As
described previously [13,14], TAM-1 HIV-1 RT unblocked AZT-
Table 2. Mutations and polymorphisms associated with A360V.
Sample ID HIV-1 RT Domain
Polymerase Connection RNase H
3a V35L, T39A, M41Lb, E42E/K, R83K, E122K, L210L/W,
L214F, T215Y, K275R, R277K, E291D, E297K
E328D, I329V, A360V,
T376A, T377S, V435I
S447N, T468S, L491S, K540K/R, N519S
4 V35I/V, D67N, K70R, R83K, K104K/N, Q207E, R211K,
L214F, T215I, K219E, V245E, P272A, R277K, T286A, E297K
I329L, T338S, R356K, T357M,
A360A/V, E399D
A446S, S447N, T468S, L491S, N519C/S/T,
A554T
4 clonec V35I, D67N, K70R, R83K, Q207E, R211K, L214F,
T215I, K219E, V245E, P272A, R277K, T286A, E297K
I329L, T338S, R356K, T357M,
A360V, V365I, E399D
A446S, S447N, D460N, T468S, L491S,
N519T, A554T
6 K70R, R83K, E122K, D123D/E, S162C/Y, I178I/L,
R211K, L214F, R277K, K281R, T286A/T, E297K
I329L, F346F/H/L/Y, R356K/R,
T357M, A360A/V, T376S,
T377S/T, V381I, E399D/E, T400I/T
V435I, S447N, T468S, N519S, A554T
11 K20K/R, D67D/N, T69S, K70R, K103K/R, Q174K, Q207E,
R211K, K219K/Q, V245M, P272A, R277K, I293V, E312A
G333E, Q334H, A360V, K390R,
Q394P/Q, V435I/V
S447N, K451K/R, L452L/V, N460D, T468P,
K512R, N519S, A554A/S, V559I/V
11 clone T69S, K70R, Q174K, Q207E, R211K, V245M,
K263R, P272A, R277K, I293V, E312A
G333E, Q334H, A360V, K390R,
V435I
S447N, K451R, N460D, T468P, K512R, N519S
29 T69S, K70R, R83K, E122K, S162C/Y, L214F,
P272A, Q278H, T286A, K311K/R
T357M, G359S, A360A/V, T376A S447N, T468S, L491S, N519S
31 K70K/R, E122K, D123E, D177E, T200A/T, Q207E,
R211K, L214F, V245K, T253A/T, L282L/P, V292I, I293V
Q334L, T357M, A360A/V, T376A,
T400A, E404D
S447N, L452E/L/V, N460D, T468P, N519N/S,
K527N, K530K/R, A554A/T, V559I/V
aMutations/polymorphisms of the viral population in each participant sample compared to consensus subtype B RT (Los Alamos HIV Sequence Database);
bTAMs highlighted in bold;
cMutations/polymorphisms of an individual participant-derived recombinant clone when compared to consensus subtype B RT (Los Alamos HIV Sequence Database).
doi:10.1371/journal.pone.0031558.t002
Table 3. Pattern of emergence of resistance mutations among participants who selected A360V.
Participant # Reached Study Endpoint? Pre-Therapy (Week 0) Earliest Sample (Week)a Last -On-Therapy Sample (Week)b
3 Yes None K70K/R, T215S/T, A360A/Vc (20) M41L, T215Y, A360V (104)
4 Yes None D67N, K70R, T215I/T, K219E/K (32) D67N, K70R, T215I, K219E, A360A/V (56)
6 No None A360A/Vc (20) K70R, A360A/V (44)
11 No None K70K/R, T215S/T, A360A/Vc (20) D67D/N, K70R, K219K/Q, A360V (152)
29 No None K70R, A360A/V (32) K70R, A360A/V (128)
31 No None None (8) K70R, A360A/V (20)
aSample obtained at earliest available time point after treatment initiation and which mutations were present compared with the pre-therapy sample.
bSample obtained at time point of last-on-therapy sample available. Participants 3 and 4 reached a study endpoint. Participants 6, 11, 29 and 31 did not reach a study
end-point.
cFor participants 6 and 11, mutation A360V occurred in ,25% of the viral population which is difficult to identify by population sequencing.
doi:10.1371/journal.pone.0031558.t003
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MP chain-terminated primers efficiently on both DNA/DNA and
RNA/DNA T/Ps (Figure 1A, 1B). Introduction of the A360V
mutation into either wildtype or TAM-1 RT increased the
enzyme’s excision activity on the RNA/DNA T/P but not on the
DNA/DNA T/P (Figure 1A, 1B). We previously delineated the
relationship between AZT-MP excision efficiency and RNase H
activity on the RNA/DNA T/P substrate used in these
experiments [23,24]. These studies showed that the primary
polymerase-dependent RNase H cleavage of RT does not impact
the enzyme’s AZT-MP excision efficiency, but polymerase-
independent RNase H cleavages that reduce the RNA/DNA
duplex length to less than 12 nucleotides abolish AZT-MP excision
activity [23,24]. In light of these data, we next evaluated the
RNase H activity of the wildtype and mutant RTs that occurred
during the ATP-mediated excision reactions described in
Figure 1B. The A360V mutation was found to significantly reduce
the frequency of a polymerase-independent cleavage event that
decreases the RNA/DNA duplex to 10 nucleotides (Figure 1C,
1D). Taken together, these findings are consistent with the concept
that A360V in HIV-1 RT impacts the efficiency of the AZT-MP
excision reaction by an RNase H-dependent mechanism.
Discussion
Recent studies show that RT inhibitors select for drug resistance
mutations in the connection domain of RT including N348I and
the A360V mutation reported here. The drug or drugs responsible
for the selection of these connection domain mutations, however,
are not well defined. For example, Yap et al reported that failure of
AZT and nevirapine therapy was associated with the emergence of
N348I, TAMs, and the non-nucleoside RT inhibitor resistance
mutations K103N, V108I, Y181C/I and G190A/S [13]. By
contrast, von Wyl et al reported that N348I predominantly
emerged in participants receiving lamivudine and AZT [15],
whereas Hachiya et al reported that N348I emerged on AZT-
and/or ddI-containing therapies [27]. Of note, the A360V
mutation has not been associated with failure of any specific drug
combinations [28]. The limitation of these prior studies is that they
relied on retrospective analyses of sequences in clinical databases.
As such, RT sequences were obtained from participants exposed
to multiple RT inhibitors, without pretherapy or longitudinal
sequences available, making it difficult to pinpoint the specific
drug or drugs responsible for mutation selection.
Table 4. AZT susceptibility of recombinant viruses containing participant-derived RT sequences.
Sample ID EC50 (mM)
a Fold-Rb (Mutant vs WT) p-valuec Fold-Rd (360 V vs 360 A) p-valuee
Wildtypef 0.2160.14 - - - -
11Clone Revertant 0.8360.18 4.0 0.0002 2.1 0.019
0.3960.11 1.9 0.0060
4 Clone Revertant 9.0962.30 43 ,0.0001 1.6 0.048
5.6562.18 27 ,0.0001
3 Full-Length RT 3 Pol Domain RT 3.8560.44 18 ,0.0001 2.3 0.010
1.6760.46 7.9 ,0.0001
aMean 6 standard deviation from 3–11 independent experiments.
bFold-resistance calculated by dividing EC50 of mutant virus by EC50 of wildtype (WT).
cCalculated using means of log10 transformed EC50 values and two-sided Student’s t test.
dFold-resistance calculated by dividing EC50 of 360 V virus by EC50 of 360 A virus.
eCalculated using means of log10 transformed EC50 values and two-sided Student’s t test.
fWildtype is xxLAI 3D (see Methods).
doi:10.1371/journal.pone.0031558.t004
Table 5. AZT susceptibility of site-directed mutant HIV-1.
Site-Directed Mutant EC50 (mM)
b Fold-Rc (WT vs Mutant) p-valued Fold-Re (360 V vs 360 A) p-valuef
Wildtype (WT)a 0.2360.11 - - - -
A360V 0.4160.11 1.8 0.022 - -
D67N/K70R 1.2260.50 5.3 ,0.0001 1.9 0.022
D67N/K70R/A360V 2.3060.88 10 ,0.0001
TAM-1 3.4160.55 15 ,0.0001 2.1 0.006
TAM-1/A360V 7.3162.71 32 ,0.0001
aWildtype (WT) is xxHIV-1LAI.
bMean 6 standard deviation from 4–6 independent experiments.
cAverage fold-resistance (Fold-R) of site-directed mutant EC50 versus wildtype (WT).
dCalculated using means of log10 transformed EC50 values and two-sided Student’s t test.
eAverage Fold-R of 360 V versus A360 recombinant virus EC50.
fCalculated using means of log10 transformed EC50 values and two-sided Student’s t test.
doi:10.1371/journal.pone.0031558.t005
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Figure 1. ATP-mediated AZT-MP excision activity and RNase H activity of wildtype, A360V, TAM-1 and TAM-1/A360V HIV-1 RT. A)
Isotherms of ATP-mediated AZT-MP excision reactions carried out by wildtype and mutant HIV-1 RT on a DNA/DNA T/P. Data are the mean 6
standard deviation from at least three independent experiments. Reaction times were: wildtype and A360V=10, 20, 30, 45, 60, 75, 90, 105 min; TAM-1
and TAM-1/A360V= 3, 7.5, 15, 25, 35, 45, 60, 75 min. B) Isotherms of ATP-mediated AZT-MP excision reactions carried out by wildtype and mutant
HIV-1 RT on an RNA/DNA T/P. Data are the mean 6 standard deviation from at least three independent experiments. Reaction times were: wildtype
and A360V=15, 30, 45, 60, 75, 90, 105, 120 min; TAM-1 and TAM-1/A360V= 3, 7.5, 15, 25, 35, 45, 60, 75 min. C) Representative autoradiogram of the
RNase H cleavage activity of the wildtype and mutant HIV-1 RTs. Experiments were carried out as described in the Materials and Methods. The reaction
times were wildtype and A360V= 15, 30, 45, 60, 75, 90, 105, 120 min; TAM-1 and TAM-1/A360V=3, 7.5, 15, 25, 35, 45, 60, 75 min. D) Isotherms for the
accumulation of the 210 product formed by wildtype and mutant HIV-1 RT during AZT-MP excision.
doi:10.1371/journal.pone.0031558.g001
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In the current study, we compared paired pre- and on-therapy
full-length RT sequences from 23 participants who had received
only AZT monotherapy in ACTG study 175. Our analyses reveal
that the A360V mutation in the connection domain emerged with
similar or higher frequency as TAMs M41L, D67N, L210W and
K219E/Q. Longitudinal analyses also showed that A360V was
detected at the same time or after the appearance of TAMs but
not before. Importantly, we also show that the A360V mutation
confers ,2.0-fold AZT resistance both in the full-length RT
sequence context it was selected in vivo and in the xxLAI molecular
clone. This is the first study to take a systematic experimental
approach to determine whether AZT alone selects for mutations in
the C-terminal domains of HIV-1 RT. As a result, both the
selection of A360V during AZT monotherapy and resistance to
AZT from A360V are unequivocally shown.
We previously reported that in in vitro selection experiments
HIV-1 selected for two novel mutations – A371V in the
connection domain and Q509L in the RNase H domain – in
combination with D67N, K70R and T215F that together
conferred greater than 100-fold AZT resistance [16]. The
A360V mutation was not selected. In the 23 on-treatment samples
sequenced in the current study, we noted a strong trend (p= 0.06)
toward selection of A371V with AZT monotherapy. By contrast,
the Q509L mutation was not present in any of the sequences.
These findings indicate that the drug pressure and other
environmental factors that promote resistance selection differ
between participants and cell culture and the results of in vitro
experiments cannot always be extrapolated in vivo.
Of note, the N348I mutation was not identified in any of the
sequences in this study. Although our sample size is small (N=23),
this is surprising given that N348I and A360V mutations decrease
AZT susceptibility to the same extent (this study, [13]).
Furthermore, the phenotypic mechanisms by which these
mutations confer AZT resistance are similar (this study, [13,26])
in that they both diminish the frequency of secondary RNase H
cleavage events that reduce the RNA/DNA duplex length of the
T/P and diminish the efficiency of AZT-MP excision. Additional
virological and biochemical analyses may provide insights into this
conundrum.
In summary, this study of full-length RT sequences from paired
pre- and post-therapy samples shows that the A360V mutation in
the connection domain of RT emerges on AZT monotherapy with
similar frequency as TAMs in the polymerase domain and confers
,2-fold resistance to AZT through an excision-promoting
molecular mechanism. These findings provide additional insight
into the importance of the connection domain of RT in resistance
to NRTI and NNRTI.
Materials and Methods
Cells and Reagents
MT-2 cells were cultured in RPMI 1640 (Whittaker MA
Bioproducts, Walkersville, MD) supplemented with 10% fetal
bovine serum (FBS), 2 mM L-glutamine, 10 mM HEPES buffer,
50 IU/mL of penicillin and 50 mg/mL of streptomycin. The P4/
R5 HeLa reporter cell line was maintained in Dulbecco’s Modified
Eagle Medium, Phenol Red Free (Gibco-BRL, Grand Island, NY)
supplemented with 10% FBS, 50 IU/mL of penicillin, 50 mg/mL
of streptomycin and 0.5 mg/mL of puromycin (Clontech, Palo
Alto, CA). P4/R5 cells were provided by Dr. Nathaniel Landau
(NYU School of Medicine, New York, NY). MT-2 cells and AZT
were obtained from the NIH AIDS Research and Reference
Reagent Program. AZT-TP was purchased from TriLink
Biotechnologies (San Diego, CA). RNA and DNA oligonucleotides
were synthesized by Integrated DNA Technologies (Coralville,
IA).
Participant Samples
All samples were obtained from participants enrolled in the
AIDS Clinical Trials Group (ACTG) study 175 (ClinicalTrials.gov
number, NCT00000625) [17]. ACTG 175 was a randomized,
double-blind, placebo-controlled trial designed to compare AZT
or didanosine monotherapy to AZT/didanosine or AZT/
zalcitabine combination therapy. Participants provided written
informed consent and the study was approved at each site by an
institutional review board. In Text S1, we list the institutions and
investigators that participated in ACTG 175. ACTG approval was
sought for the current study and was obtained through the
appropriate New Works Concept Sheet (NWCS 304).The primary
study endpoint was defined by: i) confirmed CD4 count 50%
below the average of two pre-treatment counts; ii) AIDS related
endpoints defined by the 1987 CDC criteria [18]; or iii) death.
For the current study, samples were selected from participants
who were randomized to receive AZT monotherapy, had reached
a study endpoint and for whom stored serum samples were
available at pre-therapy (week 0) and from at least 1 of 3
longitudinal time points (weeks 8, 20 or 32). Samples were also
obtained from participants who were randomized to receive AZT
monotherapy but did not reach a study endpoint. HIV-1 RNA in
serum was quantified using the Roche Amplicor Monitor HIV-1
Ultrasensitive Assay Kit 1.5 (Roche Diagnostics Corporation,
Indianapolis, IN).
Full-length RT sequencing
Viral RNA was extracted from serum samples using the
QIAampH Viral RNA Mini kit (Qiagen, Valencia, CA). RNA
was converted to cDNA and full-length HIV-1 RT was amplified
using SuperScriptTM III One-Step RT-PCR System with
PlatinumH Taq High Fidelity (Invitrogen, Carlsbad, CA) using
first-round RT-PCR primers: 59-AGGAAGAT GGAAAC-
CAAAAATGATAG-39 and 59-CCTTGACTTTGGG GATTG-
TAGGGAA-39 and second round PCR primers: 59-AGGAA-
GATGGAAACCAA A AATGATAG-39 and 59-CACAGC-
TGGCTACTATTTCTTTGC- 39. PCR products were purified
with ExoSAP-ITH (USB, Cleveland, OH), population sequenced
using the Big Dye terminator kit (v.3.1) on an ABI 3100 automated
DNA sequencer (Applied Biosystems, Foster City, CA) and
compared to consensus subtype B RT (Los Alamos HIV Sequence
Database; http://www.hiv.lanl.gov). Bidirectional sequences were
assembled and analyzed using Sequencher 4.9 software (Gene
Codes Corporation, Ann Arbor, MI). Sequencing peaks that were
greater than 25% of the total peak heights were counted as
mutations. All sequences were HIV-1 subtype B (REGA HIV-1
Subtyping Tool Version 2.0 [19]).
Production of infectious recombinant virus containing
participant-derived RT sequences
The full-length infectious HIV-1 clone pxxLAI [20] was
modified by site-directed mutagenesis to introduce silent mutations
into RT at codons 321–323, 358, 417–418, 554 and in integrase at
codons 29–31 to generate the unique restriction sites BstBI, MluI,
HpaI, NgoMIV and SgrAI, respectively (pxxLAI-3D). Next, an RT
defective cloning vector pxxLAI-3DDnp was developed by
deletion of RT polymerase domain codons 113 to 315, using
restriction sites NsiI to PflmI, as described previously [20]. To
clone participant derived full-length RTs into pxxLAI-3DDnp, the
restriction enzyme sites BclI and SgrAI were first added to the 59
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and 39 ends of genotyping amplicons using the primers: Bcl-
forward (59-GTTTTATCAAAGTAAGACAGTATGATCAGA-
TAC-39) and Sgr-reverse (59- CTACCACCGGTGGCAGGTTA
-39). PCR products and pxxLAI-3DDnp were digested with BclI
and SgrAI to form 1.89 kb full-length RT inserts and a 9.87 kb
pxxLAI-3D cloning vector. Vector and full-length RT inserts were
ligated with T4 DNA ligase (NEB, Ipswich, MA) and transformed
into C2925 cells (NEB, Ipswich, MA). Individual recombinant
clones or bulk plasmid populations were isolated and DNA
sequenced to confirm similarity with the RT sequences in the
serum sample from which they were derived. To clone the DNA
polymerase domain of participant derived RTs into pxxLAI-
3DDnp, the restriction enzyme sites BclI and BstBI were first
added to the 59 and 39 ends of genotyping amplicons using the
primers: Bcl-forward (59-GTTTTATCAAAGTAAGACAGTAT-
GATCAGATAC-39) and Bst-reverse (59- CTATTAAGT-
CTTTCGAAGGGTCATAATAC -39). PCR products and
pxxLAI-3DDnp were digested with BclI and BstBI to form
1.08 kb full-length RT inserts and a 10.68 kb pxxLAI-3D cloning
vector. Vector and full-length RT inserts were ligated and
transformed, as described above. The bulk plasmid population
of participant-derived, RT polymerase domain recombinant
clones was isolated and DNA sequenced to confirm similarity
with the RT sequences in the serum sample from which they were
derived.
Site-directed mutagenesis (QuickChangeH II XL Site-Directed
Mutagenesis Kit; Agilent, La Jolla, CA) was used to revert the
360 V mutation (codon GTC) to the wildtype amino acid (360 A;
codon GCC) in participant-derived full-length recombinant
clones. Individual recombinant clones were then isolated and
sequenced to confirm reversion. Infectious virus for AZT
susceptibility assays was generated and titered as described
previously [21].
Production of site-directed mutants containing A360V
The A360V mutation was also introduced by site-directed
mutagenesis (QuickChangeH II Site-Directed Mutagenesis Kit;
Agilent, La Jolla, CA) into the backbone of wildtype HIV-1 RT
and into RTs that contained the D67N/K70R or M41L/L210W/
T215Y (TAM-1) mutations in the p6HRT plasmid. The mutated
RT sequences were then cloned into pxxLAI and infectious virus
was generated and titered as described previously [21].
Drug susceptibility testing
The AZT susceptibility of participant-derived recombinant
virus and site-directed mutants were determined in P4/R5 cells as
described previously [21]. Briefly, three-fold dilutions of inhibitor
were added to P4/R5 cells in triplicate and cells were infected with
an amount of virus that produced ,100 relative units of light
(RLU) in no drug control wells. After 48 hours, cells were lysed
(Gal-Screen; Tropix/Applied Biosystems, Foster City, CA) and the
RLU was measured using a ThermoLabSystems luminometer
(Waltham, MA). The concentration of drug required to inhibit
viral replication by 50% (EC50) was determined from 3–11
independent experiments.
Biochemical analyses of recombinant HIV-1 RT
containing A360V
HIV-1 RTs containing the A360V, TAM-1 or TAM-1/A360V
mutations were purified to homogeneity as described previously
[22]. The ability of the recombinant enzymes to facilitate the
ATP-mediated removal of AZT-monophosphate (MP) from chain-
terminated DNA/DNA and RNA/DNA template/primers (T/Ps)
using assay systems and conditions that have been studied
extensively in the Sluis-Cremer laboratory [13,14,23,24]. For
these assays a 26-nucleotide DNA primer (pr26; 59-
CCTGTTCGGGCGCCACT GCTAGAGAT-39) was 59-radio-
labeled with [c-32P]ATP and chain-terminated with AZT-MP to
generate PAZT. PAZT was then annealed to either a 35-nucleotide
DNA (TDNA; 59-AGAATGGAAAATCTCTAGCAGT GGCGC-
foCCGAACAG-39) or RNA (TRNA: 59-AGAAUGGAAAAUCU-
CUAGCAGUGGCGCCCGAACAG-39) template. Excision as-
says were carried out by first incubating 20 nM TRNA/PAZT or
TDNA/PAZT with 3 mM ATP, 10 mM MgCl2, 1 mM dTTP and
10 mM ddCTP in a buffer containing 50 mM Tris-HCl (pH 7.5)
and 50 mM KCl. Reactions were initiated by the addition of
200 nM wildtype or mutant RT. Aliquots were removed at
defined times and analyzed as described previously [13,14,23,24].
RNase H activity was evaluated using the same AZT-MP chain-
terminated RNA/DNA T/P substrate described above, except the
59-end of the RNA was 32P-end-labelled. Assays were carried out
using 20 nM TRNA/PAZT, 3 mM ATP and 10 mM MgCl2 in a
buffer containing 50 mM Tris-HCl (pH 7.5) and 50 mM KCl.
Reactions were initiated by the addition of 200 nM wildtype or
mutant HIV-1 RT.
Statistical Analyses
The statistical significance of HIV-1 RNA levels in pre-therapy
and last-on-therapy serum samples was calculated using the
Mann-Whitney rank sum test. To identify mutations selected by
AZT monotherapy, paired pre-therapy and last-on-therapy
sequences from each participant were examined for known NRTI
resistance mutations in the polymerase domain using the
International AIDS Society – USA (IAS-USA) 2010 resistance
table [25] and for novel mutations in the polymerase, connection
and the RNase H domains of RT. The statistical significance
(p,0.05) of differences in mutant frequency between pre-therapy
and last-on-therapy sequences was determined using a two-sided
exact McNemar’s test. Due to small sample size, statistical
significance was determined using N=23 (5 participants who
reached a study endpoint and 18 participants who did not) and p-
values were unadjusted for multiple comparisons. For drug
susceptibility data, the concentration of drug required to inhibit
viral replication by 50% (EC50) were log10 transformed and
compared for significant differences (p-value,0.05) using the two-
sample Student’s t test.
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